Clinical Trials Directory

Trials / Unknown

UnknownNCT01250847

Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)

Phase IV Study of Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
83 (estimated)
Sponsor
Severance Hospital · Academic / Other
Sex
All
Age
20 Years – 35 Years
Healthy volunteers
Accepted

Summary

The primary objective of this study is to assess the effects of 'Seroquel-XR' on the verbal learning ability in people with at-risk mental state (ARMS) over a 12 week period. The verbal learning ability will be indexed by delayed free recall score of CVLT(California Verbal learning Test), a standard neuropsychological verbal memory tests. The secondary objective is to assess the effects of 'Seroquel-XR' on other cognitive function and psychiatric symptoms including psychotic, anhedonic symptoms, and impulsivity. The cognitive function abilities will be measured by standard neuropsychological tests as follows; * Working memory: verbal \& spatial 2-back test * Attention: Digit Span, 3-7 CPT(Continuous Performance Test) * Executive function: WCST (Wisconsin Card Sorting Test) * Visuo-spatial ability: Rey Complex Figure Task copy * Visuomotor speed and planning: Trail making test A \& B * Verbal fluency: Controlled Oral Word Association Test(COWAT) The scales of psychiatric symptoms which will be used are as follows; * Psychotic symptoms: Scales of Prodromal scales (SOPS), Positive and negative syndrome scale (PANSS) * Anhedonia: Social Anhedonia Scale (SAS), Physical Anhedonia Scale (PAS) * Social cognition: Ambiguous Intention Hostility Questionnaire (AIHQ) * Impulsivity: Barrett Impulsivity Scale (BIS)

Conditions

Interventions

TypeNameDescription
DRUGQuetiapine(Seroquel-XR) 50~800mg a dayThe only ARMS subjects will be given 50\~800mg Seroquel-XR once daily for total of 12 weeks.

Timeline

Start date
2010-11-01
Primary completion
2011-10-01
Completion
2012-10-01
First posted
2010-12-01
Last updated
2011-08-19

Locations

2 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01250847. Inclusion in this directory is not an endorsement.